GSK’s Witty: China Moving Rapidly To ‘No Growth’ Status
This article was originally published in PharmAsia News
Despite a first-quarter slump, GSK insists its China business is moving back to underlying growth, although the firm’s CEO warns the country's overall pharma market has "slowed down dramatically" and is moving quickly to "no-growth" status.
You may also be interested in...
The second quarter saw continued declines in GSK's China and wider emerging markets business, but CEO Andrew Witty expects a return to growth in these sectors over the remainder of the year.
After a decade-long wait, China has finally approved its first HPV vaccine, GSK's Cervarix, handing a lead to the UK-based firm over its US competitor Merck in the world’s second largest pharma market. But with Chinese companies also vying for a slice of the pie, the battle is just beginning, and pricing will be a key element.
Highly promising results for a novel, easy to use form of CAR therapy, as early trial in hematologic malignancies shows a high response and low toxicity.